Ani Pharmaceuticals (ANIP) Cash from Operations (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Cash from Operations data on file, last reported at 58375000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 66.83% year-over-year to 58375000.0; the trailing twelve-month figure through Mar 2026 stood at 208609000.0 (up 158.37% YoY), and the FY2025 full-year result was 185225000.0, up 189.34% from the prior year.
• Cash from Operations advanced to 58375000.0 in Q1 2026, from 30367000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 75812000.0 in Q2 2025 to a low of 18942000.0 in Q1 2022.
• A 5-year average of 23257235.29 and a median of 20626000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 4865.15% in 2022 and soared 1116.82% in 2023, its largest moves.
• Tracing ANIP's Cash from Operations over 5 years: stood at 4400000.0 in 2022, then soared by 1116.82% to 44740000.0 in 2023, then plunged by 64.55% to 15860000.0 in 2024, then jumped by 91.47% to 30367000.0 in 2025, then jumped by 92.23% to 58375000.0 in 2026.
• Business Quant data shows ANIP's Cash from Operations at 58375000.0 in Q1 2026, 30367000.0 in Q4 2025, and 44055000.0 in Q3 2025.